Research programme: respiratory disease therapy - Bayer/Pharmagene

Drug Profile

Research programme: respiratory disease therapy - Bayer/Pharmagene

Latest Information Update: 19 Jul 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer; Pharmagene
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Respiratory tract disorders

Most Recent Events

  • 26 May 2005 Discontinued - Preclinical for Respiratory tract disorders in United Kingdom (unspecified route)
  • 21 Jun 2001 Profile reviewed by Pharmagene
  • 16 Mar 2001 Preclinical development for Respiratory tract disorders in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top